Synageva Biopharma Corp and to-BBB to collaborate on brain drug delivery for rare diseases

10-Jan-2011 - USA

Synageva BioPharma Corp. and to-BBB technologies BV have entered into a research collaboration to evaluate the potential of transporting therapeutic proteins across the blood-brain barrier into the central nervous system (CNS).  The blood-brain barrier, a protective filter for the CNS, can be an obstacle for protein therapeutics and prevent these treatments from reaching their site of action within the CNS.  A number of rare diseases that could benefit from protein therapeutics have a CNS component and require the therapies to be transported across the blood-brain barrier.  This research collaboration will be the basis for a development program for therapies for multiple such rare diseases, including Lysosomal Storage Diseases (LSDs).

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances